Biochemical Pharmacology volume 80, issue 5, P638-646 2010 DOI: 10.1016/j.bcp.2010.04.005 View full text
|
|
Share
Keith T. Flaherty, Igor Puzanov

Abstract: Since late 2005 six new drugs have been approved by the Food and Drug Administration (FDA) for the treatment of metastatic renal cell carcinoma (RCC). However, the similarity of these agents with regard to mechanism of action makes it unclear if each agent has unique clinical utility. This flurry of drug development activity stems from the understanding of the central role that loss of von Hippel Lindau (VHL) gene function plays in the pathophysiology of clear cell RCC. The first agent to establish the therape…

expand abstract